Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous efgartigimod PH20 in adults with bullous pemphigoid
MOH_2023-03-06_012397Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Feb 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on MOH_2023-03-06_012397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-06_012397.